Effective treatment of disseminated peritoneal colon cancer with new replication-competent herpes simplex viruses

Hepato-Gastroenterology

Volumn 50, Issue 52, 2003, Pages 961-966

  Kimata, Hideto ^a,b   Takakuwa, Hiroki ^a   Goshima, Fumi ^a   Teshigahara, Osamu ^a,b   Nakao, Akimasa ^b   Kurata, Takeshi ^c   Sata, Tetsutaro ^c   Nishiyama, Yukihiro ^a  

^a NAGOYA UNIVERSITY   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

Author keywords

Disseminated peritoneal colorectal cancer; Herpes simplex virus type 1 (HSV 1); HF10; Hh101; Oncolytic herpes viral therapy

Indexed keywords

ANTINEOPLASTIC AGENT; HF10; HF101; HH101; ONCOLYTIC VIRUS; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; DISSEMINATED CANCER; DRUG EFFICACY; DRUG SAFETY; FEMALE; GENE STRUCTURE; HERPES SIMPLEX VIRUS; IMMUNE RESPONSE; IMMUNOCYTOCHEMISTRY; KNOCKOUT GENE; MOUSE; NONHUMAN; PERITONEUM CANCER; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR IMMUNITY; VIRUS GENOME; VIRUS MUTANT; VIRUS REPLICATION; VIRUS VIRULENCE;

ANIMALS; COLONIC NEOPLASMS; DISEASE MODELS, ANIMAL; FEMALE; HERPESVIRUS 1, HUMAN; IMMUNOHISTOCHEMISTRY; INJECTIONS, INTRAPERITONEAL; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; REMISSION INDUCTION; TUMOR CELLS, CULTURED; VIRULENCE; VIRUS REPLICATION;

EID: 0037663712     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Kooby DA, Carew JF, Halterman MW, Mack JE, Bertino JR, Blumgart LH, Federoff HJ, Fong Y: Oncolytic viral therapy for human colorectal cancer and liver metastases using a multi-mutated herpes simplex virus type-1*G207*. FASEB J 1999; 13:1325-1334.
2. Yoon SS, Tanabe KK: Multidisciplinary management of metastatic colorectal cancer. Surg Oncol 1998; 7:197-207.
3. Coffey MC, Strong JE, Forsyth PA, Lee PW: Reovirus therapy of tumors with activated Ras pathway. Science 1998; 282:1332-1334.
4. Culver KW, Ram Z, Wallbridge S, Ishii H, Oldfield EH, Blaese RM: In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 1992; 256:1550-1552.
5. Qazilbash MH, Xiao X, Seth P, Cowan KH, Walsh CE: Cancer gene therapy using a novel adeno-associated virus vector expressing human wild-type p53. Gene Ther 1997; 4:675-682.
6. Ring CJ: Cytolytic viruses as potential anti-cancer agents. J Gen Virol 2002; 83:491-502.
7. Wong RJ, Kim SH, Joe JK, Shah JP, Johnson PA, Fong Y: Effective treatment of head and neck squamous cell carcinoma by an oncolytic herpes simplex virus. J Am Coll Surg 2001; 193:12-21.
8. Andreansky S, Soroceanu L, Flotte ER, Chou J, Markert JM, Gillespie GY, Roizman B, Whitley RJ: Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors. Cancer Res 1997; 57:1502-1509.
9. Boviatsis EJ, Park JS, Sena-Esteves M, Kramm CM, Chase M, Efird JT, Wei MX, Breakefield XO, Chiocca EA: Long-term survival of rats harboring brain neoplasms treated with ganciclovir and a herpes simplex virus vector that retains an intact thymidine kinase gene. Cancer Res 1994; 54:5745-5751.
10. Cozzi PJ, Malhotra S, Mcauliffe P, Kooby DA, Federoff HJ, Hyuryk B, Johnson P, Scardino PT, Heston WDW, Fong Y: Intravesical oncolytic viral therapy using attenuated, replication-competent herpes simplex viruses G207 and Nv1020 is effective in the treatment of bladder cancer in an orthotopic syngeneic model. FASEB J 2001; 15:1306-1308.
11. Markert JM, Medlock MD, Rabkin SD, Gillespie GY, Todo T, Hunter WD, Palmer CA, Feigenbaum F, Tornatore C, Tufaro F, Martuza RL: Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther 2000; 7:867-874.
12. Todo T, Rabkin SD, Sundaresan P, Aiguo WU, Meehart KR, Herscowitz HB, Martuza RL: Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus. Hum Gene Ther 1999; 10:2741-2755.
13. Advani SJ, Chung SM, Yah SY, Gillespie GY, Markert JM, Whitley RJ: Replication-competent, nonneuroinvasive genetically engineered herpes virus is highly effective in the treatment of therapy-resistant experimental human tumors. Cancer Res 1999; 59:2055-2058.
14. Chahlavi A, Rabkin SD, Todo T, Sundaresan P, Martuza RL: Effect of prior exposure to herpes simplex virus 1 on viral vector-mediated tumor therapy in immunocompetent mice. Gene Ther 1999; 6:1751-1758.
15. Martuza RL: Conditionally replicating herpes vectors for cancer therapy. J Clinical Invest 2000; 105:841-847.
16. Meignier B, Martin B, Whitley RJ, Roizman B: In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020. II. Studies m immunocompetent and immunosuppressed owl monkeys (Aotus trivirgatus). J Infect Dis; 1990; 2:313-321.
17. Mohr I, Sternberg D, Ward S, Leib D, Mulvey M, Gluzman Y: A herpes simplex virus type 1 *34.5 second-site suppressor mutant that exhibits enhanced growth in cultured glioblastoma cells is severely attenuated in animals. J Virol 2001; 75:5189-5196.
18. Yamada Y, Kimura H, Morishima T, Daikoku T, Maeno K, Nishiyama Y: The pathogenicity of ribonucleotide reductase-null mutants of herpes simplex virus type 1 in mice. J Infect Dis 1991; 164:1091-1097.
19. Kasuya H, Nishiyama Y, Nomoto S, Hosono J, Takeda S, Nakao A: Intaperitoneal delivery of hrR3 and ganciclovir prolongs survival in mice with disseminated pancreatic cancer. J Surg Oncol 1999; 72:136-141.
20. Moriuchi S, Oligino T, Krisky D, Marconi P, Fink D, Cohen J, Glorioso JC: Enhanced tumor cell killing in the presence of ganciclovir by herpes simplex virus type 1 vector-directed coexpression of human tumor necrosis factor-alpha and herpes simplex virus thymidine kinase. Cancer Res 1998; 58:5731-5737.
21. Nishiyama Y, Kimura H, Daikoku T: Complementary lethal invasion of the central nervous system by nonneuroinvasive herpes simplex virus type 1 and 2. J Virol 1990; 65:4520-4524.
22. Nishiyama Y, Yamada Y, Kurachi R, Daikoku T: Construction of a US3 lacZ insertion mutant of herpes simplex virus type 2 and characterization of its phenotype in vitro and in vivo. Virology 1992; 190:256-268.
23. Sundaresan P, Hunter WD, Martuza RL, Rabkin SD: Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation in mice. J Virol 2000; 74:3832-3841.
24. Koshizuka T, Gishima F, Takakuwa H, Nozawa N, Daikoku T, Koiwai O, Nishiyama Y: Identification and characterization of the UL56 gene product of herpes simplex virus type 2. J Virol 2002; 76:6718-6728.
25. Takakuwa H, Goshima F, Nozawa N, Yoshikawa T, Kimata H, Nakao A, Kurata T, Sata T, Nishiyama Y: Oncolytic viral therapy using a spontaneously generated herpes simplex virus type 1 variant for disseminated peritoneal tumor in immunocompetent mice. Arch Virol; (In press)